Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. B. Smaill

Specific, Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

1998

English

Related publications

Nucleotide Binding by the Epidermal Growth Factor Receptor Protein-Tyrosine Kinase

Journal of Biological Chemistry

English

Pertuzumab Increases Epidermal Growth Factor Receptor Down-Regulation by Counteracting Epidermal Growth Factor Receptor-ErbB2 Heterodimerization

Molecular Cancer Therapeutics

Cancer Research

Oncology

2009

English

Is There a Role for Dacomitinib, a Second-Generation Irreversible Inhibitor of the Epidermal-Growth Factor Receptor Tyrosine Kinase, in Advanced Non-Small Cell Lung Cancer?

Expert Opinion on Pharmacotherapy

Medicine

Pharmacology

2020

English

ZD1839 (‘Iressa’), a Specific Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Potentiates Radiotherapy in a Human Colorectal Cancer Xenograft Model

British Journal of Cancer

Cancer Research

Oncology

2002

English

Insulin-Like Growth Factor-I Receptor Blockade by a Specific Tyrosine Kinase Inhibitor for Human Gastrointestinal Carcinomas

Molecular Cancer Therapeutics

Cancer Research

Oncology

2008

English

Lung Cancer Cells Survive Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Exposure Through Upregulation of Cholesterol Synthesis

FASEB BioAdvances

2019

English

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Biomedical Journal

Medicine

2015

English

Local Administration of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor May Provide a New Therapeutic Potential for the Treatment of Intractable Upper Airway Inflammation

Journal of Japan Society of Immunology & Allergology in Otolaryngology

2016

English

Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. B. Smaill

Specific, Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor

Related publications

Nucleotide Binding by the Epidermal Growth Factor Receptor Protein-Tyrosine Kinase

Pertuzumab Increases Epidermal Growth Factor Receptor Down-Regulation by Counteracting Epidermal Growth Factor Receptor-ErbB2 Heterodimerization

Is There a Role for Dacomitinib, a Second-Generation Irreversible Inhibitor of the Epidermal-Growth Factor Receptor Tyrosine Kinase, in Advanced Non-Small Cell Lung Cancer?

ZD1839 (‘Iressa’), a Specific Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Potentiates Radiotherapy in a Human Colorectal Cancer Xenograft Model

Insulin-Like Growth Factor-I Receptor Blockade by a Specific Tyrosine Kinase Inhibitor for Human Gastrointestinal Carcinomas

Lung Cancer Cells Survive Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Exposure Through Upregulation of Cholesterol Synthesis

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Local Administration of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor May Provide a New Therapeutic Potential for the Treatment of Intractable Upper Airway Inflammation

Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma